RemeGen Co., Ltd. Announces Discloseable RMB 453 Million Investment in Wealth Management Products
Key Highlights
- Investment Size: RemeGen Co., Ltd. has invested a total of RMB 453 million in four wealth management products using idle self-owned funds.
- Transaction Date: Agreements were signed on May 14, 2026 following Board approval on March 27, 2026.
- Product Types & Risk: Products range from fixed-income to mixed asset classes, with low-to-medium and medium risk ratings.
- Issuer: All products are issued by Huatai Securities Co., Ltd. (HTSC), a leading PRC securities company.
- Listing Rules: The aggregated investment triggers a discloseable transaction under Chapter 14 of the Hong Kong Listing Rules, requiring reporting and announcement.
Transaction Details
On May 14, 2026, RemeGen entered into four separate agreements with HTSC for the purchase of wealth management products:
- HTSC Wealth Management Product Agreement No. 1: RMB 60 million
- Name: Guoshou Asset – Yuanliu 2158 Insurance Asset Management Product
- Type: Fixed-income
- Risk Rating: Low-to-medium
- Term: No fixed term; redemption at subscriber’s discretion
- Yield: Market-based, subject to uncertainty
- Investment Scope: Debt assets
- HTSC Wealth Management Product Agreement No. 2: RMB 75 million
- Name: Huatai Zijin Weekly Subscription 6-Month Rolling Hold Bond Initiation Securities Investment Fund
- Type: Fixed-income
- Risk Rating: Low-to-medium
- Term: No fixed term; redemption at subscriber’s discretion
- Yield: Market-based, subject to uncertainty
- Investment Scope: Broad range of liquid financial instruments, including government and corporate bonds, asset-backed securities, repurchase agreements, deposits, stocks (including ChiNext), and other instruments allowed by CSRC
- HTSC Wealth Management Product Agreement No. 3: RMB 102 million
- Name: Shengxinxiang – Huatai WEFUND Fixed Income Private FOF 1066 Separate Asset Management Plan
- Type: Fixed income
- Risk Rating: Low-to-medium
- Term: 10 years; actual period subject to exit date
- Yield: Market-based, subject to uncertainty
- Investment Scope: Financial products and cash-type assets
- HTSC Wealth Management Product Agreement No. 4: RMB 216 million
- Name: Shengxinxiang – Huatai WEFUND Private FOF 1068 Separate Asset Management Plan
- Type: Mixed
- Risk Rating: Medium
- Term: 10 years; actual period subject to exit date
- Yield: Market-based, subject to uncertainty
- Investment Scope: Financial products and cash-type assets
Strategic Rationale and Shareholder Considerations
- Enhancing Capital Efficiency: The Board aims to revitalize idle funds and improve capital utilization by investing in wealth management products rather than leaving funds in bank deposits.
- Risk Management: Products are selected for their controllable risk profiles, expected to offer yields higher than bank time deposits.
- Independent Transaction: HTSC and its owners are confirmed as independent third parties, mitigating related party concerns.
- Price Sensitivity: The investment and its expected returns could positively impact RemeGen’s financial performance, potentially affecting share price, especially as the transaction is classified as “discloseable” under HKEX rules.
- Transparency: Full disclosure ensures shareholders are informed of significant capital allocation decisions.
Board Statement
The Board considers the terms to be fair and reasonable, on normal or better commercial terms, and in the best interests of the Company and its shareholders.
Company Profile
RemeGen Co., Ltd. is a commercial-ready biopharmaceutical company focused on innovative biologics for autoimmune, oncology, and ophthalmic diseases in China and globally.
Potential Impact
For Investors: This sizeable allocation of RMB 453 million into diversified, professionally managed wealth management products signals proactive capital management. The expected higher yields versus traditional deposits and improved capital utilization may strengthen RemeGen’s financial position, which could be viewed positively by the market and influence share price performance. However, actual returns are subject to market conditions and product-specific risks.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Actual results and impacts may vary based on market conditions and company performance.
RemeGen有限公司公佈4.53億元人民幣財富管理產品投資詳情
重點摘要
- 投資規模：RemeGen以閒置自有資金，總共投資4.53億元人民幣於四項財富管理產品。
- 交易日期：協議於2026年5月14日簽訂，董事會早於2026年3月27日批准。
- 產品種類與風險：產品涵蓋固定收益及混合資產類，風險評級為低至中等。
- 發行方：全部產品由華泰證券股份有限公司（HTSC）發行。
- 上市規則：總投資額觸及港交所上市規則第14章「須披露交易」門檻，需報告及公告。
交易詳情
RemeGen於2026年5月14日與HTSC簽定四份財富管理產品協議：
- 協議一：人民幣6,000萬元
- 產品名稱：國壽資產–源流2158保險資產管理產品
- 類型：固定收益
- 風險：低至中等
- 期限：無固定期限，按申購人贖回日決定
- 預期收益：隨市場波動，具不確定性
- 投資範圍：債券資產
- 協議二：人民幣7,500萬元
- 產品名稱：華泰紫金週申購六個月滾動持有債券發起證券投資基金
- 類型：固定收益
- 風險：低至中等
- 期限：無固定期限，按申購人贖回日決定
- 預期收益：隨市場波動，具不確定性
- 投資範圍：包括國債、企業債、資產證券、回購協議、存款、股票（包括創業板）等流動金融工具
- 協議三：人民幣1.02億元
- 產品名稱：晟信翔–華泰WEFUND固定收益私募FOF1066單獨資產管理計劃
- 類型：固定收益
- 風險：低至中等
- 期限：10年，實際期限依退出日期而定
- 預期收益：隨市場波動，具不確定性
- 投資範圍：金融產品及現金類資產
- 協議四：人民幣2.16億元
- 產品名稱：晟信翔–華泰WEFUND私募FOF1068單獨資產管理計劃
- 類型：混合
- 風險：中等
- 期限：10年，實際期限依退出日期而定
- 預期收益：隨市場波動，具不確定性
- 投資範圍：金融產品及現金類資產
戰略原因及股東須知
- 提升資金效率：董事會希望藉財富管理產品活化閒置資金，提高資金利用率。
- 風險管理：產品風險整體可控，預期收益高於同期銀行定存。
- 獨立交易：HTSC及其最終實益人與公司無關聯，消除關聯交易疑慮。
- 價格敏感：此舉或提升公司財務表現，對股價有正面影響，屬於「須披露交易」。
- 透明度：重大資金配置決策全面披露，保障股東知情權。
董事會聲明
董事會認為協議條款公平合理，屬於正常或更優商業條件，符合公司及股東整體利益。
公司簡介
RemeGen是一家商業化生物製藥公司，主攻自身免疫、腫瘤及眼科疾病創新生物藥物，業務覆蓋中國及全球。
潛在影響
對投資者：公司主動將4.53億元閒置資金投入多元化財富管理產品，預期收益高於傳統存款，資金利用效率提升，或增強財務狀況，市場或正面看待，股價有機會受影響。但實際收益取決於市場及產品風險。
免責聲明
本文章只供參考，不構成任何投資建議。實際結果及影響或因市場及公司表現而異。
